Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4884249 | 0.91 | KMT2A (0.43) | ALDH1A1MEN1KMT2APOLBMAPK1 | |
| SCHEMBL4894518 | 0.89 | TSHR (0.39) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| SCHEMBL4890196 | 0.89 | MAPK1 (0.37) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| SCHEMBL4892541 | 0.89 | POLB (0.39) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| SCHEMBL21067812 | 0.86 | ALDH1A1 (0.45) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| SCHEMBL14103285 | 0.85 | MAPT (0.39) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| SCHEMBL4892495 | 0.82 | POLB (0.40) | ALDH1A1MEN1KMT2APOLBMAPK1 | |
| SCHEMBL4884288 | 0.81 | ALDH1A1 (0.41) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| SCHEMBL14103287 | 0.81 | HRH4 (0.35) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| SCHEMBL14102812 | 0.80 | POLB (0.37) | ALDH1A1MAPTMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | SSU72, POLR2H, POLR2E | ALDH1A1 276/4885MAPT 3976/4885MEN1 3917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.